




RealRate

PHARMACEUTICAL 2019

Lexaria Bioscience Corp.
Rank 363 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Lexaria Bioscience Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lexaria Bioscience Corp. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 477% points. The greatest weakness of Lexaria Bioscience Corp. is the variable Other Expenses, reducing the Economic Capital Ratio by 1,906% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,958%, being 1,627% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	2,284
Cost of Goods Sold	25
Intangible Assets	0
Liabilities, Current	44
Liabilities, Non-Current	0
Other Assets	147
Other Compr. Net Income	-14
Other Expenses	6,307
Other Liabilities	0
Other Net Income	0
Property and Equipment	1.2
Research and Development	493
Revenues	433
Selling, General and Administrative Expense	218

Output Variable	Value in 1000 USD
Assets	2,432
Liabilities	44
Expenses	7,042
Stockholders Equity	2,388
Net Income	-6,609
Comprehensive Net Income	-6,616
Economic Capital Ratio	-1,958%